PD Dr. Fabian Müller

Medizinische Fakultät Department of Medicine 5 – Haematology and Oncology Professur für CAR-T-Zell-Therapie

TriCAM (NCT02976558) – a randomized controlled pilot study of complementary medicine in allogeneic stem cell transplantation to improve quality of life (2025) Behzad A, Krause S, Mackensen A, Müller F, Stark A, Völkl S, Rösler W Journal article Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment (2025) Pelzl R, Benintende G, Gsottberger F, Scholz JK, Rübner M, Yao H, Wendland K, et al. Journal article Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma (2025) Shumilov E, Scholz JK, Seib M, Mazzeo P, Wurm-Kuczera R, Vucinic V, Holtick U, et al. Journal article One CHiP to rule them all? Mechanistic insight into carfilzomib-induced lung injury with neutrophil extracellular trap formation following cellular immunotherapy (2025) Scholz JK, Stabel L, Schwingen NR, Knopf J, Flatt AS, Bäuerle T, Krause S, et al. Journal article, Medical case study BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells (2025) Müller F, Wirsching A, Hagen M, Völkl S, Tur C, Raimondo MG, Taubmann J, et al. Journal article Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study (2025) Hagen M, Müller F, Wirsching A, Kharboutli S, Spörl S, Düsing C, Krickau T, et al. Journal article Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study (2025) Merz M, Albici AM, von Tresckow B, Rathje K, Fenk R, Holderried T, Müller F, et al. Journal article Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma (2025) Müller F, Schwingen NR, Hagen M, Scholz JK, Aigner M, Wirsching A, Taubmann J, et al. Journal article Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy (2024) Merz M, Dima D, Hashmi H, Ahmed N, Stölzel F, Holderried TA, Fenk R, et al. Journal article Treatment of CNS systemic lupus erythematosus with CD19 CAR T cells (2024) Hagen M, Müller F, Wirsching A, Kharboutli S, Spörl S, Aigner M, Völkl S, et al. Journal article